Results 141 to 150 of about 146,874 (392)

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo, Innocent Gerald Asiimwe, Sudeep Pushpakom, Carlo Palmieri, Munir Pirmohamed   +4 more
wiley   +1 more source

Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]

, 2017
Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia, DE IULIIS, Francesca, Lanza, Rosina, Salerno, Gerardo, Scarpa, Susanna, Taglieri, Ludovica   +5 more
core   +1 more source

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Journal of Clinical Oncology, 2019
PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
S. Tolaney, Hao Guo, S. Pernas, William T. Barry, D. Dillon, Lauren Ritterhouse, Bryan P. Schneider, F. Shen, K. Fuhrman, Michele Baltay, C. Dang, D. Yardley, B. Moy, P. Marcom, K S Albain, H. Rugo, M. Ellis, I. Shapira, A. C. Wolff, L. Carey, B. Overmoyer, A. Partridge, C. Hudis, I. Krop, H. Burstein, E. Winer   +25 more
semanticscholar   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, EarlyView.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Early diagnostic value of novel biomarkers for breast cancer therapy‐related cardiac dysfunction

ESC Heart Failure, EarlyView.
Our meta‐analysis revealed significant post‐treatment increases in GDF‐15, CRP, MPO, and PLGF levels (Gal‐3 unchanged) among breast cancer patients. Only elevated MPO levels were significantly associated with an increased risk of cancer therapy‐related cardiac dysfunction (CTRCD).
Zhengwei Wang, Yujuan Wu, Jingyi He, Diansa Gao, Zhong Zuo   +4 more
wiley   +1 more source

Kardiotoksiske effekter av trastuzumab

Tidsskrift for Den norske legeforening, 2011
Breast cancer with overexpression of the HER2 receptor is an aggressive type of breast cancer with poor prognosis. Trastuzumab (Herceptin) is a monoclonal antibody that binds to the HER2 receptor on the cell surface blocking the signals that promote cell-growth proliferation. Trastuzumab treatment has almost halved the risk of relapse, when given as an
Erik Wist, Jan Hysing
openaire   +3 more sources

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

Cellular Physiology and Biochemistry, 2017
Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-positive breast cancer, but an increasing incidence of trastuzumab resistance has been observed clinically during the past decade.
Xiangdong Lu, Jingjing Ma, Jiahui Chu, Qing Shao, Yao Zhang, Guangping Lu, Jun Li, Xiang Huang, Wei Li, Yongfei Li, Yang Ling, Tao Zhao   +11 more
doaj   +1 more source